Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights
  • Choose License Type

Global Tissue Plasminogen Activator Market, By Drug Type (Alteplase, Reteplase and Tenecteplase), By Application (Ischemic Stroke, Myocardial Infarction, Pulmonary Embolism, Thrombolysis, and others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 2,455.4 million in 2020 and is expected to exhibit a CAGR of 5.2% over the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

The increasing number of pipeline products for the treatment of acute ischemic stroke is expected to fuel growth of the global tissue plasminogen activator market in the near future.

For instance, in 2018, Chiesi Farmaceutici S.p.A., a biopharmaceutical company, initiated the investigational clinical trial study on safety and efficacy of the alteplase for the treatment of catheter occlusion in individuals. The study is currently in phase III clinical trial and is expected to be completed by December 2021.

Moreover, in 2019, University of Calgary, a research university in Canada, initiated the investigational clinical trials study on alteplase in comparison with tenecteplase for the treatment of acute ischemic stroke. The study is currently in phase III clinical trial and is expected to be completed by December 2022.

Global Tissue Plasminogen Activator Market– Impact of Coronavirus (Covid-19) Pandemic

The COVID-19 pandemic caused major disruptions to clinical trial execution in the U.S., impacting key stakeholders across the industry. Investigative site capabilities experienced upheaval, driven by staff furloughs, social-distancing protocols, financial losses, and concerns over patient safety. Sponsors, CROs (Contract research organization), and other organizations that support drug development shifted to remote working environments. An estimated 80% of non-COVID-19 trials were stopped or interrupted as a result of the COVID-19 pandemic.

Recently, the U.S. FDA guidance (March 2020 and updated July 2020) acknowledged that the impact of COVID-19 may require companies conducting clinical trials to consider virtual patient visits or put new processes in place of current protocols. Therefore, there are more opportunities for using remote healthcare including conducting virtual or decentralized trials, site-less clinical trials, and use of other non-conventional approaches that do not involve in-person visits.

Moreover, various research institutes and academic research centers are focusing on research and development in tissue plasminogen activator for the treatment of the patients suffering from Acute Respiratory Distress Syndrome and COVID-19 infections

For instance, in July 2020, Negovsky Reanimatology Research Institute, a research institute in Moscow, initiated the investigational clinical trial study on the Impact of Tissue Plasminogen Activator (tPA) Treatment for an Atypical Acute Respiratory Distress Syndrome (COVID-19) (AtTAC). The study is currently in the phase 3 clinical trial and uses combination of tissue plasminogen activator (Alteplase) and ringer lactate solution for the treatment of patients suffering with an Atypical Acute Respiratory Distress Syndrome (COVID-19) (AtTAC).

Browse 26 Market Data Tables and 29 Figures spread through 141 Pages and in-depth TOC on “Tissue Plasminogen Activator Market”- Global Forecast to 2020, By Drug Type (Alteplase, Reteplase and Tenecteplase), By Application (Ischemic Stroke, Myocardial Infarction, Pulmonary Embolism, Thrombolysis, and others), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in the Global Tissue Plasminogen Activator Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/tissue-plasminogen-activator-market-2469

Academic institutes and research institutes are focused on the research and development of alteplase for the treatment of disease conditions such as acute ischemic stroke, which is expected to drive growth of the market over the forecast period. 

For instance, in 2019, University of Calgary, a research university in Canada, initiated the investigational clinical trials study on alteplase in comparison with tenecteplase for the treatment of acute ischemic stroke. The study is currently in phase III clinical trial and is expected to be completed by December 2022

Key Takeaways of the Global Tissue Plasminogen Activator Market:

  • The global tissue plasminogen activator market is expected to exhibit a CAGR of 5.2% over the forecast period, owing to increasing approval of drug by the regulatory authorities. For instance, in 2018, Wacker Biotech GmbH, a biopharmaceutical company, announced that it received the U.S. Food and Drug Administration approval to manufacture reteplase and it will be marketed by Chiesi Pharmaceuticals Inc.
  • Among drug type, Alteplase segment accounted for the largest market share in 2020, Alteplase is a fibrinolytic agent and a tissue plasminogen activator. It is used for the treatment of various disease conditions such as acute ischemic stroke, pulmonary embolism, acute myocardial infarction, and occluded catheters.
  • Key players operating in the global tissue plasminogen activator market include F. Hoffmann-La Roche AG, Boehringer Ingelheim GmbH, CHIESI Farmaceutici S.p.A., Gennova Biopharmaceuticals Ltd, Abbott Laboratories, and Reliance Life Sciences
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner